Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “FLT3 Gene Mutation”

65 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 65 results

Testing effectiveness (Phase 2)WithdrawnNCT03760445
What this trial is testing

HDM201 Added to CT in R/R or Newly Diagnosed AML

Who this might be right for
Leukemia, Myeloid, Acute
Novartis Pharmaceuticals
Large-scale testing (Phase 3)Study completedNCT02421939
What this trial is testing

ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation

Who this might be right for
Leukemia, Acute Myeloid (AML)
Astellas Pharma Global Development, Inc. 371
Testing effectiveness (Phase 2)Ended earlyNCT04209725
What this trial is testing

CPX-351 (Vyxeos™) With Quizartinib for the Treatment of FLT3-ITD Mutation-Positive Acute Myeloid Leukemia

Who this might be right for
Leukemia, Myeloid, Acute
SCRI Development Innovations, LLC 1
Testing effectiveness (Phase 2)Looking for participantsNCT06561880
What this trial is testing

The Efficacy of Triple Regimen in Newly Diagnosed AML Patients With FLT3 Mutation

Who this might be right for
FLT3 Gene MutationAML
Institute of Hematology & Blood Diseases Hospital, China 66
Testing effectiveness (Phase 2)UnknownNCT03135054
What this trial is testing

Combination of Quizartinib and Omacetaxine Mepesuccinate for AML Carrying FLT3-ITD

Who this might be right for
AMLFLT3-ITD Mutation
The University of Hong Kong 40
Early research (Phase 1)Looking for participantsNCT06313437
What this trial is testing

Revumenib in Combination With 7+3 + Midostaurin in AML

Who this might be right for
Acute Myeloid LeukemiaAML, AdultAML With Gene Mutations+2 more
Richard Stone, MD 22
Not applicableUnknownNCT05383014
What this trial is testing

FLT3-ITD Gene Mutation and CD135 Expression in Acute Myeloid Leukemia.

Who this might be right for
Acute Myeloid Leukemia
Assiut University 82
Not applicableUnknownNCT03547258
What this trial is testing

Italian Non-Interventional Study of FLT3 Mutated AML Patients

Who this might be right for
AMLFLT3-ITD MutationFLT3-TKD Mutation
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS 800
Testing effectiveness (Phase 2)Study completedNCT02984995
What this trial is testing

Phase 2 Study of Quizartinib in Participants With Acute Myeloid Leukemia (AML) FLT3 Internal Tandem Duplication (FLT3/ITD) Mutation

Who this might be right for
Leukemia, Myeloid, Acute
Daiichi Sankyo Co., Ltd. 37
Testing effectiveness (Phase 2)Looking for participantsNCT06022003
What this trial is testing

Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia

Who this might be right for
AML, AdultRefractory AMLRelapsed Adult AML+2 more
French Innovative Leukemia Organisation 33
Testing effectiveness (Phase 2)Study completedNCT01831726
What this trial is testing

Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib

Who this might be right for
Tumor Pathway Activations Inhibited by Dovitinib
Novartis Pharmaceuticals 80
Testing effectiveness (Phase 2)Study completedNCT03170895
What this trial is testing

Combination of Sorafenib and Omacetaxine Mepesuccinate in Newly Diagnosed or Relapsed/Refractory AML Carrying FLT3-ITD

Who this might be right for
AMLFLT3-ITD Mutation
The University of Hong Kong 5
Testing effectiveness (Phase 2)Looking for participantsNCT07259707
What this trial is testing

Gilteritinib Plus VA Followed By Consolidation Chemotherapy in Newly Diagnosed FLT3-ITD+ AML

Who this might be right for
Acute Myeloid LeukemiaFLT3 Internal Tandem Duplication PositiveIntermediate Risk Acute Myeloid Leukemia+1 more
First Affiliated Hospital of Zhejiang University 25
Early research (Phase 1)Looking for participantsNCT07162116
What this trial is testing

Evaluate the Effect of XY0206 on the QTc Interval in Chinese Healthy Participants

Who this might be right for
Acute Myeloid Leukemia With FLT3/ITD Mutation
Shijiazhuang Yiling Pharmaceutical Co. Ltd 45
Testing effectiveness (Phase 2)Looking for participantsNCT04140487
What this trial is testing

Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm

Who this might be right for
Recurrent Acute Myeloid LeukemiaRecurrent Chronic Myelomonocytic LeukemiaRecurrent Myelodysplastic/Myeloproliferative Neoplasm+3 more
M.D. Anderson Cancer Center
Testing effectiveness (Phase 2)Active Not RecruitingNCT04062266
What this trial is testing

AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission

Who this might be right for
Acute Myeloid Leukemia in RemissionFLT3 Gene MutationHematologic and Lymphocytic Disorder+3 more
M.D. Anderson Cancer Center 50
Early research (Phase 1)Ended earlyNCT03552029
What this trial is testing

Milademetan Plus Quizartinib Combination Study in FLT3-ITD Mutant Acute Myeloid Leukemia (AML)

Who this might be right for
Acute Myeloid Leukemia
Daiichi Sankyo 10
Large-scale testing (Phase 3)Study completedNCT02752035
What this trial is testing

ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy

Who this might be right for
Acute Myeloid Leukemia (AML)Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation
Astellas Pharma Global Development, Inc. 183
Testing effectiveness (Phase 2)Ended earlyNCT03333486
What this trial is testing

Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer

Who this might be right for
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveAcute Leukemia in RemissionAcute Lymphoblastic Leukemia+34 more
Roswell Park Cancer Institute 31
Testing effectiveness (Phase 2)Study completedNCT02927262
What this trial is testing

ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission

Who this might be right for
Acute Myeloid Leukemia (AML)Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) / Internal Tandem Duplication (ITD) Mutation
Astellas Pharma Global Development, Inc. 98
Load More Results
97